Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand

Dorthe Skovgaard; Morten Persson; Andreas Kjaer

doi:10.1016/j.cpet.2017.02.003

Urokinase Plasminogen Activator Receptor–PET with ⁶⁸Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand

Dorthe Skovgaard, Morten Persson, Andreas Kjaer^*

^*Corresponding author af dette arbejde

4 Citationer (Scopus)

Abstract

Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using ⁶⁸Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with ⁶⁸Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.

Originalsprog	Engelsk
Tidsskrift	PET Clinics
Vol/bind	12
Udgave nummer	3
Sider (fra-til)	311-319
Antal sider	9
ISSN	1556-8598
DOI	https://doi.org/10.1016/j.cpet.2017.02.003
Status	Udgivet - 2017

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1016/j.cpet.2017.02.003

Citationsformater

@article{59299ef610c74ee8b902ebab512898d6,

title = "Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand",

abstract = "Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.",

keywords = "Breast cancer, Invasiveness, Molecular imaging, Oncology, PET, Prognostication, Prostate cancer, Theranostics",

author = "Dorthe Skovgaard and Morten Persson and Andreas Kjaer",

year = "2017",

doi = "10.1016/j.cpet.2017.02.003",

language = "English",

volume = "12",

pages = "311--319",

journal = "P E T Clinics",

issn = "1556-8598",

publisher = "W.B.Saunders Co.",

number = "3",

}

TY - JOUR

T1 - Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105

T2 - First Clinical Experience with a Novel PET Ligand

AU - Skovgaard, Dorthe

AU - Persson, Morten

AU - Kjaer, Andreas

PY - 2017

Y1 - 2017

N2 - Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.

AB - Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.

KW - Breast cancer

KW - Invasiveness

KW - Molecular imaging

KW - Oncology

KW - PET

KW - Prognostication

KW - Prostate cancer

KW - Theranostics

U2 - 10.1016/j.cpet.2017.02.003

DO - 10.1016/j.cpet.2017.02.003

M3 - Review

C2 - 28576169

AN - SCOPUS:85017274030

SN - 1556-8598

VL - 12

SP - 311

EP - 319

JO - P E T Clinics

JF - P E T Clinics

IS - 3

ER -